We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

NSC:NYSENorfolk Southern Corporation Analysis

Data as of 2026-06-03 - not real-time

$305.11

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Norfolk Southern (NSC) is trading at $305.11, comfortably above its 20‑day SMA of 313.15, 50‑day SMA of 305.06 and 200‑day SMA of 294.74, indicating a short‑term bullish bias despite a neutral RSI of 44.3 and a bearish MACD histogram of –1.84, which suggests lingering downside momentum. Volatility is elevated at roughly 32% over the past 30 days, but the stock’s beta of 0.45 points to lower market‑wide risk, and volume remains stable around 670K shares daily, supporting liquidity.
Fundamentally, NSC delivers solid operating margins (32% operating, 22% profit) and a healthy free cash flow generation of $1.30 B, underpinning a dividend yield of 1.76% with a payout ratio near 45%, well within sustainable limits. The forward PE of 22.6 is below the industry average PE of 30.1, and the model‑based upside of ~10% versus a DCF fair value suggests the stock is at least fairly valued, if not modestly undervalued. The most material catalyst is the pending merger with Union Pacific, currently under STB review, which adds regulatory uncertainty in the short term but promises significant strategic synergies and valuation uplift if approved.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Regulatory pause on the Union Pacific merger
  • Bearish MACD signal
  • Price near recent support at $301.26

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Potential approval of the $85 B merger
  • Valuation upside of ~10% and PE advantage
  • Strong cash flow supporting dividend and growth

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • Integrated network delivering economies of scale
  • Sustainable dividend and low beta exposure
  • Stable U.S. domestic freight demand

Key Metrics & Analysis

Financial Health

Revenue Growth0.20%
Profit Margin21.91%
P/E Ratio25.7
ROE17.61%
ROA5.89%
Debt/Equity111.59
P/B Ratio4.3
Op. Cash Flow$3.8B
Free Cash Flow$1.3B
Industry P/E30.1

Technical Analysis

TrendBullish
RSI44.4
Support$301.26
Resistance$326.00
MA 20$313.15
MA 50$305.06
MA 200$294.74
MACDBearish
VolumeStable
Fear & Greed Index92.75

Valuation

Fair Value$4.54
Target Price$335.29
Upside/Downside9.89%
GradeFair
TypeValue
Dividend Yield1.76%

Risk Assessment

Beta0.45
Volatility32.26%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.